Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 4
1947 16
1948 26
1949 13
1950 23
1951 38
1952 27
1953 34
1954 51
1955 63
1956 52
1957 45
1958 76
1959 84
1960 64
1961 88
1962 91
1963 175
1964 216
1965 152
1966 161
1967 193
1968 204
1969 186
1970 197
1971 216
1972 167
1973 203
1974 179
1975 180
1976 157
1977 172
1978 176
1979 214
1980 215
1981 266
1982 287
1983 326
1984 385
1985 425
1986 389
1987 442
1988 397
1989 417
1990 436
1991 398
1992 432
1993 408
1994 385
1995 381
1996 496
1997 527
1998 568
1999 604
2000 555
2001 578
2002 587
2003 674
2004 710
2005 716
2006 877
2007 891
2008 884
2009 828
2010 878
2011 977
2012 1035
2013 1098
2014 1253
2015 1190
2016 1162
2017 1173
2018 1181
2019 1133
2020 91386
2021 137049
2022 126803
2023 86175
2024 55513
2025 5476

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

475,072 results

Results by year

Filters applied: . Clear all
Page 1
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. Cao B, et al. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187464 Free PMC article. Clinical Trial.
Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard
Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS: In hospitalized
BET 1: Lopinavir-ritonavir and COVID-19.
Dolan D, Ingham J, Baombe J. Dolan D, et al. Emerg Med J. 2020 Jul;37(7):450-451. doi: 10.1136/emermed-2020-210221.2. Emerg Med J. 2020. PMID: 32616658 Review. No abstract available.
Lopinavir-ritonavir for COVID-19: A living systematic review.
Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. Verdugo-Paiva F, et al. Medwave. 2020 Jul 15;20(6):e7967. doi: 10.5867/medwave.2020.06.7966. Medwave. 2020. PMID: 32678815 English.
OBJECTIVE: Provide a timely, rigorous, and continuously updated summary of the evidence on the role of lopinavir/ritonavir in the treatment of patients with COVID-19. METHODS: We conducted searches in the special L.OVE (Living OVerview of Evidence) pla …
OBJECTIVE: Provide a timely, rigorous, and continuously updated summary of the evidence on the role of lopinavir/ritonavir in …
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
Amani B, Khanijahani A, Amani B, Hashemi P. Amani B, et al. J Pharm Pharm Sci. 2021;24:246-257. doi: 10.18433/jpps31668. J Pharm Pharm Sci. 2021. PMID: 34048671 Free article.
There was no significant difference between lopinavir/ritonavir and chloroquine as well as lopinavir/ritonavir and hydroxychloroquine regarding the efficacy outcomes (P>0.05). ...However, this difference was not significant regarding other ef …
There was no significant difference between lopinavir/ritonavir and chloroquine as well as lopinavir/ritonavi
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M, Servillo G, Einav S. Vargas M, et al. Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659. Eur Rev Med Pharmacol Sci. 2020. PMID: 32894567 Free article.
Three case reports and one retrospective study described the use of lopinavir/ritonavir in MERS. Twenty-two papers describe the use of lopinavir/ritonavir in adult patients with COVID-19. CONCLUSIONS: The existing literature does not suff …
Three case reports and one retrospective study described the use of lopinavir/ritonavir in MERS. Twenty-two papers describe th …
Psychopharmacology of COVID-19.
Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Bilbul M, et al. Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18. Psychosomatics. 2020. PMID: 32425246 Free PMC article. Review.
The only Food and Drug Administration-approved drug to treat COVID-19 is remdesivir, and other off-label medications used include chloroquine and hydroxychloroquine, tocilizumab, lopinavir/ritonavir, favipiravir, convalescent plasma therapy, azi …
The only Food and Drug Administration-approved drug to treat COVID-19 is remdesivir, and other off-label medications used incl …
Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
Qomara WF, Primanissa DN, Amalia SH, Purwadi FV, Zakiyah N. Qomara WF, et al. Int J Gen Med. 2021 Nov 23;14:8557-8571. doi: 10.2147/IJGM.S332458. eCollection 2021. Int J Gen Med. 2021. PMID: 34849001 Free PMC article. Review.
A combination of favipiravir with other supportive therapy showed more favorable outcomes for COVID-19 patients. Furthermore, the use of lopinavir/ritonavir in COVID-19 patients reported no significant clinical improvement compared to sta …
A combination of favipiravir with other supportive therapy showed more favorable outcomes for COVID-19 patients. Furthermore, …
Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
Magro P, Zanella I, Pescarolo M, Castelli F, Quiros-Roldan E. Magro P, et al. Biomed J. 2021 Mar;44(1):43-53. doi: 10.1016/j.bj.2020.11.005. Epub 2020 Nov 10. Biomed J. 2021. PMID: 33608241 Free PMC article. Review.
Currently, there is no specific antiviral treatment for COVID-19. However, drugs previously developed to treat other viral infections are being tested to verify if they might also be effective against SARS-CoV-2, the virus that causes COVID-19. ...Ther …
Currently, there is no specific antiviral treatment for COVID-19. However, drugs previously developed to treat other viral inf …
A Trial of Lopinavir-Ritonavir in Covid-19.
Dalerba P, Levin B, Thompson JL. Dalerba P, et al. N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5. N Engl J Med. 2020. PMID: 32369281 No abstract available.
A Trial of Lopinavir-Ritonavir in Covid-19.
Carmona-Bayonas A, Jimenez-Fonseca P, Castañón E. Carmona-Bayonas A, et al. N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5. N Engl J Med. 2020. PMID: 32369285 No abstract available.
475,072 results
You have reached the last available page of results. Please see the User Guide for more information.